Collecting blood and urine samples from bladder cancer patients
Official title: Bladder Bank (a Prospective Banking Study)
Run by Mayo Clinic · NCT06109857 · Data updated 2026-11-12
This study is collecting blood and urine samples from bladder cancer patients to see if these samples can help create better tests for early detection of the disease.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1500 (estimated) |
| Sponsor | Mayo Clinic Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Rochester, Minnesota) |
| Status | Recruiting |
| Started | July 6, 2022 |
| Main results expected | December 1, 2027 |
| Study ends | December 1, 2027 |
| Registry record updated | October 14, 2026 |
| Trial ID | NCT06109857 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults over 18 years who have undergone evaluation for hematuria.
✕Probably not a fit
Patients with known cancer outside of bladder carcinoma or those with recurrent muscle invasive bladder cancer may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to establish a biobank of blood and urine samples from patients diagnosed with bladder carcinoma. The primary objective is to support the development of non-invasive tests for the early detection of bladder cancer. Participants will undergo sample collection and have their medical records reviewed while enrolled in the study. This approach allows researchers to gather valuable biological materials that can aid in advancing diagnostic methods for bladder cancer.
Why it matters
Potential benefit: If successful, this study could lead to improved early detection methods for bladder cancer, potentially increasing survival rates.
How similar studies have gone: Other studies have successfully established biobanks for cancer research, indicating that this approach has potential for meaningful contributions to early detection methods.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \> 18 years * Patient has undergone office-based evaluation for hematuria \[computed tomography (CT), ultrasound, cystoscopy\] Exclusion Criteria: * Patient has known cancer outside of the target cancer 5 years prior to current collection (not including basal cell or squamous cell skin cancers; if patient has not been seen or if information is not available, the patient is eligible) * Patient has recurrent muscle invasive bladder cancer * Patient has ever been previously diagnosed with UTUC (upper tract urothelial carcinoma) prior to bladder resection * Patient has received chemotherapy class drugs for the treatment of non-target origin cancer in the 5 years prior to current collection * Patient has had any prior radiation therapy to the target lesion prior to current collection * Patient has had a biopsy to the target organ and/or lesion within 3 days before collection * Patient has undergone cystectomy or cystoprostatectomy * Patient has transurethral instrumentation (placement of urinary catheter) within 7 days prior to urine collection * Patient has had a urinary tract infection within 14 days prior to urine collection * Patient has chronic indwelling urinary catheter
Where it's running
-
Mayo Clinic in Rochester
Rochester, Minnesota, United States Recruiting
Study contacts
- Principal investigator: John B. Kisiel, MD — Mayo Clinic in Rochester
- Study coordinator: Clinical Trials Referral Office
- Email: mayocliniccancerstudies@mayo.edu
- Phone: 855-776-0015
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
In-home cancer treatment with remote specialist support for patients in the Florida Panhandle
This program will try giving standard cancer treatments at home to people living in the Florida Panhandle and nearby areas to see if they prefer it and have better treatment satisfaction.
-
MRI-first treatment pathway for muscle-invasive bladder cancer
This trial tests whether using a multiparametric bladder MRI to skip a staging TURBt can speed up care for people with biopsy-proven muscle-invasive bladder cancer.
-
Vanguard: a new blood test approach to screen for multiple cancers
This study will test two different blood-based multi-cancer detection tests in adults 45–75 without cancer to see if they find cancers earlier than usual care.
-
Comparing quality of life and urinary outcomes after bladder surgery
This study looks at how different types of bladder surgery affect the quality of life and urinary health of patients to see which approach might be better for them.
-
Imaging study using two antibody fragments in patients with solid tumors
This study is testing two special antibody fragments in people with solid tumors to see how well they target cancer cells and how they move through the body.
-
Using light and occupational therapy to manage fatigue in cancer patients
This study is testing if combining light therapy with occupational therapy can help cancer patients with genitourinary cancers feel less tired and improve their daily activities.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.